Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer on OTC sale

This article was originally published in The Tan Sheet

Executive Summary

Bids for Pfizer's OTC division during a June 6 auction reportedly topped $15 bil., while bidders included GlaxoSmithKline, Johnson & Johnson and Reckett Benckiser. Pfizer says it is still maintaining the option of spinning the division off to shareholders 1("The Tan Sheet" May 29, 2006 p. 6 ). "The review is continuing, and we will be announcing which of the strategic options [we choose] in the third quarter," a Pfizer spokesman said...

You may also be interested in...

Pfizer Weighs Options For OTC Division As Investors Line Up For Purchase

While Pfizer considers whether to sell its Consumer Healthcare unit or spin it off to shareholders, potential buyers are placing bids with an eye toward an early June deadline

Medtech Biggest Casualty In Swiss/EU Uncertainty As Worst Case Scenario Looms

Eighteen years of free trade threatens to crash, as a result of the stalemate in the market access agreement between Switzerland and the EU. Industry association Swiss Medtech is advising local medtech manufacturers to find notified bodies and authorized representatives based in the EU. However, local company SQS remains confident of its ongoing notified body role.

Interview: OurCrowd CEO Jon Medved On Israel’s Medtech “Boomtown”

With $1.3bn invested in over 200 high-tech start-ups, OurCrowd is now sharpening its focus on medtech. Medtech Insight spoke to founder Jon Medved to find out more.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts